



Company Overview

Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros' gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and genetic diseases and is advancing a growing pipeline of gene control medicines. Syros' lead drug candidates are SY-1425, a selective RAR α agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with advanced solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.

Syros to Host Key Opinion Leader Symposium on Acute Myeloid Leukemia and Myelodysplastic Syndrome on July 17, 2018

Jul 10 2018, 8:01 AM EDT

Syros Announces Appointment of Michael W. Bonney to Its Board of Directors

Jun 14 2018, 4:01 PM EDT

Stock Overview

Symbol	SYRS
Exchange	Nasdaq
Market Cap	393.22m
Last Price	\$12.07
52-Week Range	\$6.30 - \$24.375

Investor Relations

Stern Investor Relations, Inc.
Hannah Deresiewicz
hannahd@sternir.com

Management Team

Nancy Simonian, M.D.

President and Chief Executive Officer

Eric R. Olson, Ph.D.

Chief Scientific Officer

Gerald E. Quirk

Chief Legal and Administrative Officer

David A. Roth, M.D.

Chief Medical Officer

Jeremy P. Springhorn, Ph.D.

Chief Business Officer

Joseph J. Ferra

Chief Financial Officer

Syros Pharmaceuticals, Inc.

620 Memorial Drive
Suite 300
Cambridge, MA 02139

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.